Version 1
: Received: 23 August 2023 / Approved: 24 August 2023 / Online: 25 August 2023 (11:07:02 CEST)
Version 2
: Received: 25 August 2023 / Approved: 28 August 2023 / Online: 29 August 2023 (09:24:16 CEST)
Ngaha, T.Y.S.; Zhilenkova, A.V.; Essogmo, F.E.; Uchendu, I.K.; Abah, M.O.; Fossa, L.T.; Sangadzhieva, Z.D.; D. Sanikovich, V.; S. Rusanov, A.; N. Pirogova, Y.; Boroda, A.; Rozhkov, A.; Kemfang Ngowa, J.D.; N. Bagmet, L.; I. Sekacheva, M. Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors. Cancers2023, 15, 4648.
Ngaha, T.Y.S.; Zhilenkova, A.V.; Essogmo, F.E.; Uchendu, I.K.; Abah, M.O.; Fossa, L.T.; Sangadzhieva, Z.D.; D. Sanikovich, V.; S. Rusanov, A.; N. Pirogova, Y.; Boroda, A.; Rozhkov, A.; Kemfang Ngowa, J.D.; N. Bagmet, L.; I. Sekacheva, M. Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors. Cancers 2023, 15, 4648.
Ngaha, T.Y.S.; Zhilenkova, A.V.; Essogmo, F.E.; Uchendu, I.K.; Abah, M.O.; Fossa, L.T.; Sangadzhieva, Z.D.; D. Sanikovich, V.; S. Rusanov, A.; N. Pirogova, Y.; Boroda, A.; Rozhkov, A.; Kemfang Ngowa, J.D.; N. Bagmet, L.; I. Sekacheva, M. Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors. Cancers2023, 15, 4648.
Ngaha, T.Y.S.; Zhilenkova, A.V.; Essogmo, F.E.; Uchendu, I.K.; Abah, M.O.; Fossa, L.T.; Sangadzhieva, Z.D.; D. Sanikovich, V.; S. Rusanov, A.; N. Pirogova, Y.; Boroda, A.; Rozhkov, A.; Kemfang Ngowa, J.D.; N. Bagmet, L.; I. Sekacheva, M. Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors. Cancers 2023, 15, 4648.
Abstract
Research has shown the role of growth factors in lung cancer angiogenesis. Angiogenesis promotes lung cancer progression by stimulating tumor growth, enhancing tumor invasion, contributing to metastasis, and modifying immune system responses within the tumor microenvironment. As a result, new treatment techniques based on the anti-angiogenic characteristics of compounds have been developed. These compounds selectively block the growth factors themselves, their receptors, or the downstream signaling pathways activated by these growth factors. The EGF and VEGF families are the primary targets in this approach, and several studies are being conducted to propose anti-angiogenic drugs that are increasingly suitable for the treatment of lung cancer, either as monotherapy or as combined therapy. The efficacy results are encouraging, but a caution must be placed on the higher risk of toxicity, outlining the importance of personalized follow-up in the management of these patients.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Commenter: Yvan Sinclair NGAHA TCHAWE
Commenter's Conflict of Interests: Author